Syndax’s Revuforj Earns Sturdy Doctor Assist, JP Morgan Predicts Gross sales Development – Syndax Prescription drugs (NASDAQ:SNDX)

JP Morgan launched a survey on Thursday targeted on the launch prospects of Syndax Prescription drugs Inc’s SNDX Revuforj (revumenib) in relapsed/refractory (r/r) KMT2A acute leukemias and nucleophosmin 1 mutation acute myeloid leukemia (NPM1 AML).

The FDA authorized Revuforj in November 2024 as the primary and solely menin inhibitor for r/r acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in grownup and pediatric sufferers one 12 months and older.

Revuforj generated $7.7 million in web product income throughout its first 5 weeks available on the market.

The corporate expects to submit a supplemental utility submitting for revumenib in R/R mNPM1 AML within the second quarter of 2025, adopted by a possible FDA approval round year-end 2025.

Additionally Learn: FDA Approves Incyte/Syndax Partnered Drug For Persistent Graft-Versus-Host Illness, A Publish-Transplant Complication

JPMorgan says that, on common, surveyed physicians handled 8 KMT2A acute leukemia and 12 NPM1 AML sufferers.

Total, surveyed physicians offered excessive rankings associated to Revuforj’s scientific profile in each r/r KMT2A acute leukemias and NPM1 AML.

Analyst Anupam Rama writes that surveyed physicians indicated a excessive diploma of consolation utilizing Revuforj in r/r NPM1 ought to the product be integrated into NCCN pointers.

“In our view, survey outcomes underscore that SNDX shares are at the moment materially undervalued on Revuforj within the r/r (KMT2A / NPM1) setting alone – which we worth within the ~high-$20 to low-$30s / share vary,” Rama writes.

For the close to time period, JPMorgan estimates 2025 Revuforj gross sales to be round $50 million (US solely), largely pushed by the KMT2A setting.

JPMorgan raised its value goal from $39 to $41, accounting for a quicker ramp to peak for Revuforj in each KMT2A acute leukemias and NPM1 AML, reiterating the Chubby score.

Value Motion: SNDX inventory is up 0.43% at $14.16 finally examine Friday.

Learn Subsequent:

Photograph: Shutterstock